CRVS · Corvus Pharmaceuticals, Inc.
$13.04
-0.27 (-2.03%)
At close · Jul 29
Market Cap
$1.12B
Shares
84.09M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$13.04
Open$13.36
Day$12.79–13.49
52W$3.96–26.95
Avg vol 30d1.3M
Short int18.1M · 21.5% float · 12.6d
Short vol64%
Last earningsMay 14, 2026
DataJan 2020–Jul 2026
Filing10-Q · May 7
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 7, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Neutral
Momentum
Weak
Sentiment
Very Bullish
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 18.2 · elevated
Equity put/call 0.71
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+1%
above
Price vs 50-day avg
−1%
below
RSI (14)
42
neutral
MACD trend
Negative
52-week position
39%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−13%
trailing
6-month return
−37%
trailing
YTD return
+69%
this year
Relative strength
−45%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $13 › 200d $13 — 50d above 200d
Institutional flow
Accumulating
25 of 164 funds reported for Jun 30 · net +46.0K sh shares · +5 new
Insider flow
Accumulating
Net +$333.7K over 90 days · 0% sells
Short interest
Falling
21.48% of float · ▼ -4.0% MoM · 12.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
164 holders — near 3-yr high, broad support
Squeeze score
72
high risk · 0–100
Fundamentals
EPS growth
+48%
Y/Y
Free cash flow
$-33.0M
Balance sheet
$4.6M
net cash
Quant / Vol
risk profile
Volatility
180%
annualized · 1-yr
Max drawdown
−57%
past year
ATR
6.1%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+1%
Bullish
Price vs 50-day avg
−1%
Neutral
RSI (14)
42
Neutral
MACD trend
Negative
Bearish
52-week position
39%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 4 of 6
Trend (MA cross)
No cross
50d $13 › 200d $13 — 50d above 200d
Institutional flow
Accumulating
25 of 164 funds reported for Jun 30 · net +46.0K sh shares · +5 new
Insider flow
Accumulating
Net +$333.7K over 90 days · 0% sells
Short interest
Falling
21.48% of float · ▼ -4.0% MoM · 12.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
164 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $4
Now $13 · 39%
52-wk high $27
vs 200-day avg +1%
vs 50-day avg -1%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CRVS
this stock
Corvus Pharmaceuticals, Inc.
|
$1.12B | +69.4% | — | — | 21.5% |
|
ONC
BeOne Medicines Ltd.
|
$472.90B | +8.8% | +22179.2% | 962.4 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$124.46B | +8.2% | +46.2% | 29.1 | 2.0% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$72.88B | -9.8% | +20.8% | 17.0 | 3.3% |
|
ARGX
Argenx SE
|
$54.57B | +3.7% | — | — | 2.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CRVS | -6.8% | -12.7% | -37.4% | -12.7% | +69.4% |
| SPY | -1.0% | 0.0% | +7.4% | -0.8% | +8.6% |
| vs SPY | -5.8% | -12.7% | -44.8% | -11.9% | +60.7% |
Key facts
CIK
1626971
CUSIP
221015100
13F (30d)
21 filings
21 filers
Visit website
Investor relations